New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma. Arch Pathol Lab Med. 2014;138(12):1666-72.Zhang, X.M. & Aguilera, N. 2014, "New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma", Archives of Pathology & Laboratory Medicine, vol. 138, no. 12, pp. 1666-...
3.Witzig TE, Vukov AM, Habermann TM, et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Gro...
Cutaneous B-Cell Lymphoma Diffuse Large B-Cell Lymphoma (DLBCL) Non-Hodgkin Lymphoma (NHL) Diffuse Large B-Cell Lymphoma (Non-Hodgkin Lymphoma) Treatment Protocols News & Perspective Mantle Cell Lymphoma: Drug Combo Improves PFS COVID Vaccine–Induced T-Cell Responses Help Compensate for B...
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, accounting for 30–40% of all non-Hodgkin lymphomas (NHL) in Western countries1. The introduction of chemoimmuno- therapy in the treatment of DLBCL has dramatically improved the outcome of these patients ...
Context.--B-cell non-Hodgkin lymphoma is a heterogeneous group of lymphoproliferative malignancies with different clinical behaviors and treatments. It is important to differentiate individual B-cell lymphoma to apply the best treatment and management. Morphology and immunohistochemistry are the primary tool...
Diffuse large B-cell lymphoma (DLBCL) is the most common and aggressive subtype of non-Hodgkin lymphoma (NHL), constituting 30–58% of all diagnosed NHL cases1. The current standard treatment of DLBCL is a combi- nation of Rituximab with traditional chemotherapy of cyclophosphamide-doxorubicin-...
B-NHL 可累及任何器官,致病机制、临床表现和病程具有异质性,其恶性程度从惰性至侵袭性极强不等。CD20 单抗联合常规化疗仍是大多数 B-NHL 亚型的标准治疗方案,大多数患者可从中获得持久的疗效;但高危患者容易早期复发,临床预后很...
diffuse large B-cell lymphoma (R/R DLBCL). [8]2022EHA. ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY- DRUG CONJUGATE. ...
弥漫性大B细胞淋巴瘤(Diffuse large B〆ll lymphoma, DLBCL)是世界范围内最常见的侵袭性非霍奇金淋巴瘤(non﹐dgkin lymphoma, NHL)，在中国、日本和韩国分别占所有病例的40.8%、36.0%和48.4%目前一线(1L)治疗DLBCL的标准治疗(standardゝ゛re, SoC)是抗CD20单克隆抗体利妥昔单抗(rituximab, R)联合CHOP方案(...